Trojan Bio
Therapeutic Antibodies for the Treatment of Cancer
Company Overview
Snapshot
Founded in October 2021 by Anat Burkovitz, Amir Aharoni, and Noam Diamant, Trojan Bio operates with 1–10 employees. The company has secured funding across two disclosed rounds from two investors. In December 2023, Trojan Bio received Seed funding from Peregrine Ventures.
Business overview
Trojan Bio is a preclinical immunotherapy company focused on developing novel therapeutic antibodies for various cancers. The company's core technology involves "Trojan antibodies" that integrate viral peptides to activate the immune system, labeling cancer cells as virally infected to harness powerful anti-viral immunity for cancer eradication. Trojan Bio operates within the Health Tech & Life Sciences sector, specifically targeting the Drugs Discovery & Development market within Pharmaceuticals.
Log in to access full profile ›Company Intelligence Q&A
- When was Trojan Bio founded and by whom?
- Trojan Bio was founded in October 2021 by Anat Burkovitz, Amir Aharoni, and Noam Diamant.
- What is Trojan Bio's primary focus?
- Trojan Bio is a preclinical immunotherapy company developing novel therapeutic antibodies for the treatment of various cancers.
- What is the core technology behind Trojan Bio's approach?
- Trojan Bio's core technology involves Trojan antibodies that integrate viral peptides to activate the immune system, effectively labeling cancer cells as virally infected to leverage anti-viral immunity for cancer eradication.
- Which investors have participated in Trojan Bio's funding rounds?
- Trojan Bio has received funding from Peregrine Ventures and NFX Capital.
- What is Trojan Bio's product stage?
- Trojan Bio's product is currently in the clinical trial stage.